Showing 2637 results
- Media Release /Additional analysis from pivotal Phase III SOLAR-1 clinical trial studying investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) and fulvestrant in patients with PIK3CA-mutated HR+/HER2-…
- Media Release /Biosimilar HyrimozTM (adalimumab-adaz) approved for all indications of reference medicine not protected by orphan exclusivity **Biosimilars are critical to sustaining US healthcare system, providing…
- Media Release /Late-breaking NATALEE subgroup analysis to be presented at ESMO shows invasive disease-free survival (iDFS) benefit remains consistent in all subgroups, including in patients with stage II tumors,…
- Media Release /Agreement includes a clinical trial to evaluate a combination of tropifexor (LJN452) and one or more Pfizer compounds for the treatment of non-alcoholic steatohepatitis (NASH) Novartis has…
- Media Release /Year two results consistent with previously announced key secondary endpoint data on retinal fluid (IRF and/or SRF) showing superior reductions versus aflibercept Superior reductions in…
- Featured News /
- Media Release /New Cosentyx® (secukinumab) label to include dosing flexibility up to 300 mg, based on clinical response, and 24-week structural data with subcutaneous (sc) regimens[1] Cosentyx inhibits…
- Key Release /Hausse du chiffre d'affaires net de 5% (tcc[1], +6% USD) en 2018, soutenue par l'excellente performance des moteurs de croissance: Pharmaceuticals: cette unité opérationnelle a progressé de 7% (…
- Key Release /Der Nettoumsatz steigt im Geschäftsjahr um 5% (kWk[1], +6% USD) dank starker Performance der Wachstumstreiber: Die Geschäftseinheit Pharmaceuticals wächst um 7% (kWk), getragen von Cosentyx mit…
- Media Release /Crizanlizumab is a monthly infusion under development to prevent pain crises (also called vaso-occlusive crises, or VOCs) in patients with sickle cell disease Sickle cell VOCs, which are…
Pagination
- ‹ Previous page
- 1
- …
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- …
- 264
- › Next page